This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is a Beat Likely for Patterson Companies (PDCO) in Q1 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement at both Dental and Animal Health segments.
Why The Cooper Companies (COO) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
The Cooper Companies (COO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Aurora Cannabis Inc. (ACB) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of 50% and 19.50%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Add The Cooper Companies (COO) to Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.
5 Stocks to Buy From the Prospering Dental Supplies Industry
by Indrajit Bandyopadhyay
Here we discuss five stocks from the Dental Supplies industry that are likely to create wealth for investors. These include WST, ALGN, COO, XRAY and PDCO.
Is the Options Market Predicting a Spike in The Cooper Companies (COO) Stock?
by Zacks Equity Research
Investors need to pay close attention to The Cooper Companies (COO) stock based on the movements in the options market lately.
XRAY or COO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
XRAY vs. COO: Which Stock Is the Better Value Option?
Reasons to Retain The Cooper Companies (COO) in Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.
XRAY vs. COO: Which Stock Is the Better Value Option?
by Zacks Equity Research
XRAY vs. COO: Which Stock Is the Better Value Option?
XRAY or COO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
XRAY vs. COO: Which Stock Is the Better Value Option?
Down -7.64% in 4 Weeks, Here's Why The Cooper Companies (COO) Looks Ripe for a Turnaround
by Zacks Equity Research
The Cooper Companies (COO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Cooper Companies (COO) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cooper Companies' (COO) second-quarter fiscal 2023 revenues reflect a solid segmental performance despite a year-over-year decline in earnings.
The Cooper Companies (COO) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for The Cooper Companies (COO) give a sense of how its business performed in the quarter ended April 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The Cooper Companies (COO) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of 2.33% and 1.75%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?
Bilibili (BILI) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Bilibili's (BILI) first-quarter 2023 performance will likely reflect strength in advertising revenues. However, increasing G&A and R&D expenses are expected to have kept margins under pressure.
Is a Surprise Coming for CooperCompanies (COO) This Earnings Season?
by Zacks Equity Research
CooperCompanies (COO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat Likely for Cooper Companies (COO) in Q2 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.
What Makes The Cooper Companies (COO) a New Buy Stock
by Zacks Equity Research
The Cooper Companies (COO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Adagene Inc. Sponsored ADR (ADAG) and The Cooper Companies (COO) have performed compared to their sector so far this year.
XRAY vs. COO: Which Stock Is the Better Value Option?
by Zacks Equity Research
XRAY vs. COO: Which Stock Is the Better Value Option?
Why You Should Buy The Cooper Companies (COO) Stock Now
by Zacks Equity Research
The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -51.92% and 65.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Henry Schein (HSIC) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of -2.42% and 1.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
XRAY vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
XRAY vs. COO: Which Stock Is the Better Value Option?
Cardinal Health (CAH) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 17.57% and 1.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?